C12N 2760/20271
Demonstrated in vivo effect
C12N2760/20271 (Demonstrated in vivo effect) appears on 13 US grants and 29 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 29
- Assignees
- 19
- Inventors
- 55
- Latest grant
- 15 Aug 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 3 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 6 | 6 |
| 2018 | 2 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 3 |
| 2021 | 1 | 1 |
| 2022 | 1 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 3 |
| 2025 | 0 | 4 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Replication-competent vesicular stomatitis viruses15 Aug 2023US 11,723,937 B2Mayo Foundation for Medical Education and Research
- Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic RNA viruses6 Dec 2022US 11,517,598 B2Ottawa Hospital Research Institute
- Antiviral peptide and use thereof26 Oct 2021US 11,155,582 B2National University Corporation Hokkaido University
- Replication-competent vesicular stomatitis viruses7 Apr 2020US 10,610,553 B2Mayo Foundation for Medical Education and Research
- Recombinant isfahan viral vectors3 Apr 2018US 9,932,564 B2Board of Regents, The University of Texas System
- Self-replicating rna vaccines and methods of use8 Jan 2026US 2026/0007738 A1Immorna (Hangzhou) Biotechnology Co., Ltd.
- Modified varicella zoster virus glycoprotein e proteins23 Oct 2025US 2025/0325656 A1Glaxosmithkline Biologicals SA
- Heterologous Prime Boost Vaccine9 Oct 2025US 2025/0312428 A1Boehringer Ingelheim International GmbH
- Morreton viruses and methods of use19 Jun 2025US 2025/0195591 A1Mayo Foundation for Medical Education and Research
- Recombinant live attenuated rsv vaccine strain and production method therefor24 Apr 2025US 2025/0127872 A1SK Bioscience Co., Ltd.
Most cited
By later US patents
- Replication-competent vesicular stomatitis viruses3US 9,861,668 B2Mayo Foundation for Medical Education and Research · 2018
- Replication-competent vesicular stomatitis viruses2US 9,555,067 B2Mayo Foundation for Medical Education and Research · 2017
- Replication-competent vesicular stomatitis viruses1US 10,610,553 B2Mayo Foundation for Medical Education and Research · 2020
- Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins1US 9,630,996 B22017
- Attenuated recombinant vesicular stomatitis viruses comprising modified matrix proteins1US 9,732,122 B22017